Table 1 Patient demographics for individuals of study cohort

Clinical parameter

HC

n = 25

ACPA- RA

n = 23

PsA

n = 12

UA

n = 7

CA

n = 2

SLE

n = 1

ACPA + RA

n = 14

Age, years (median (IQR))

33 (23-54.5)

62 (48–69)

46 (32.25–56.50)

49 (26–63)

60 (59–60)

38

56 (40.75-60.0)

Gender (male/female)

9/16

7/16

6/6

2/5

2/0

0/1

6/8

Disease duration, months (median (IQR))

-

3 (1–36)

12 (1–21)

1 (0–1)

1 (1–1)

0

5 (0–21)

DAS-28 (median (IQR))

-

3.78 (2.63–4.75)

4.015

4.06 (2.74–5.10)

2.7 (2.02–3.38)

6.2

4.020 (2.713–4.573)

Tender joint count 68 (median (IQR)

-

3 (1.0–17.0)

6.5 (2.25–17.75)

8 (3–17)

1.5 (1.0–2.0)

4

5.0 (0.75–11.25)

Swollen joint count 68 (median (IQR)

-

2 (0.0–5.0)

2.5 (1.25–5.75)

4 (2–5)

1 (1.0–1.0)

4

5.0 (1.5–9.25)

IgM RF positivity (yes/no)

-

7/16

1/11

2/5

0/2

0/1

11/3

CRP (mg/dl) (median (IQR))

0.5 (0.30–2.25)

3.55 (1.05–7.35)

4.95 (1.55–14.48)

2.9 (1.7–3.8)

1.9 (1.6–2.2)

9.0

4.6 (1.50–17.50)

sDMARD use (yes/no)

0/7

7/16

4/12

0/7

0/2

0/1

4/10

Prednisone use (yes/no)

0/7

1/22

0/7

0/7

0/2

0/1

0/14